Andi Permana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Andi Permana has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Aditya Indra Mahendra
Brawijaya Internal Medicine Research Center, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia
2 shared publications - Anisa Asmiragani
Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia
2 shared publications - Dessy Aprilia Kartini
Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia
2 shared publications - Erwin Alexander Pasaribu
Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia
2 shared publications - Fredo Tamara
Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, Universitas Negeri Sebelas Maret, Surakarta, Indonesia
2 shared publications - Gatot Soegiarto
Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
2 shared publications
Latest Publications
- Open Access
- 15 April 2026
- Published by Universitas Muhammadiyah Palangkaraya in PengabdianMu: Jurnal Ilmiah Pengabdian kepada Masyarakat
- Vol. 11 (4) , 1286-1292
Peningkatan Pengetahuan Kader PKK Kecamatan Banyuresmi terkait Pengelolaan Obat Sisa
PKK cadres serve as the frontline in efforts to improve community health at the household level. One health issue that is often overlooked is the presence of leftover household medicines, which, if not managed properly, can pose various risks to both family health and environmental sustainability. Medicines that are stored for too long, used without supervision, or disposed of carelessly can cause poisoning, antibiotic resistance, and contamination of soil and water. Therefore, this community service activity aims to enhance PKK cadres' knowledge and awareness of the proper and safe management of leftover household medicines in Banyuresmi Village. The method employed was an educational approach through an interactive seminar, in which participants not only received material but also engaged in discussions and practiced identifying and handling leftover medicines. The training covered topics such as obtaining medicines responsibly, using them according to proper guidelines, storing them correctly to maintain stability, and safely disposing of medicines that are no longer suitable for use. An evaluation using pre-test and post-test questionnaires administered to 50 respondents showed a highly significant improvement in participants' understanding (p < 0.0001). Additionally, participants reported that the activity was beneficial, relevant to their daily needs, and increased their confidence in providing health education to the community.
- 15 April 2026
- Published by Universitas Muhammadiyah Palangkaraya in PengabdianMu: Jurnal Ilmiah Pengabdian kepada Masyarakat
- Vol. 11 (4) , 1286-1292
Open AccessPeningkatan Pengetahuan Kader PKK Kecamatan Banyuresmi terkait Pengelolaan Obat Sisa
PKK cadres serve as the frontline in efforts to improve community health at the household level. One health issue that is often overlooked is the presence of leftover household medicines, which, if not managed properly, can pose various risks to both family health and environmental sustainability. Medicines that are stored for too long, used without supervision, or disposed of carelessly can cause poisoning, antibiotic resistance, and contamination of soil and water. Therefore, this community service activity aims to enhance PKK cadres' knowledge and awareness of the proper and safe management of leftover household medicines in Banyuresmi Village. The method employed was an educational approach through an interactive seminar, in which participants not only received material but also engaged in discussions and practiced identifying and handling leftover medicines. The training covered topics such as obtaining medicines responsibly, using them according to proper guidelines, storing them correctly to maintain stability, and safely disposing of medicines that are no longer suitable for use. An evaluation using pre-test and post-test questionnaires administered to 50 respondents showed a highly significant improvement in participants' understanding (p < 0.0001). Additionally, participants reported that the activity was beneficial, relevant to their daily needs, and increased their confidence in providing health education to the community.
- Open Access
- 29 July 2022
- Published by F1000 Research Ltd in F1000Research
- Vol. 11, 862
The global prevalence and association between the risk of myocarditis and mRNA-based COVID-19 vaccination: A network meta-analysis
Background: Cases of myocarditis development have been reported after administration of messenger ribonucleic acid (mRNA)-based coronavirus disease (COVID-19) vaccines. However, the reports vary among the studies, and the types of mRNA vaccines with potential to cause myocarditis remain unidentified. The objective was to assess the cumulative prevalence of myocarditis and determine the association between myocarditis and mRNA-based COVID-19 vaccination. Methods: We performed a network meta-analysis by searching articles in PubMed, Scopus, and Web of Science. Information on the prevalence of myocarditis after the mRNA-based COVID-19 vaccination was collected from each study. Analysis was performed by calculating the pooled prevalence rate, and the association was determined using the Z-test. Data networking was performed using the Bayesian method. Results: A total of 18 papers was included in our analysis. We found that the cumulative prevalence of myocarditis was 1.7, 1.9, 1.2, and 1.1 per 100,000 population after vaccination with different types of mRNA-based COVID-19 vaccines, namely all mRNA COVID-19 vaccines, BNT162b1, mRNA-1273, and the combination of BNT162b1 and mRNA-1273, respectively. Moreover, the results revealed that BNT162b1 vaccination increased the risk of myocarditis by 1.64- and 1.71-folds compared to mRNA-1273 and the combination of BNT162b2 and mRNA-1273, respectively. Similar risks of developing myocarditis were observed after mRNA-1273 and the combination of BNT162b1 and mRNA-1273 vaccination. Conclusions: Our findings suggest the cumulative prevalence of myocarditis after mRNA-based COVID-19 vaccination with maximum prevalence was observed after BNT162b2 administration. BNT162b2 was associated with a higher risk of developing myocarditis than the other mRNA-based COVID-19 vaccines.
- 29 July 2022
- Published by F1000 Research Ltd in F1000Research
- Vol. 11, 862
Open AccessThe global prevalence and association between the risk of myocarditis and mRNA-based COVID-19 vaccination: A network meta-analysis
Background: Cases of myocarditis development have been reported after administration of messenger ribonucleic acid (mRNA)-based coronavirus disease (COVID-19) vaccines. However, the reports vary among the studies, and the types of mRNA vaccines with potential to cause myocarditis remain unidentified. The objective was to assess the cumulative prevalence of myocarditis and determine the association between myocarditis and mRNA-based COVID-19 vaccination. Methods: We performed a network meta-analysis by searching articles in PubMed, Scopus, and Web of Science. Information on the prevalence of myocarditis after the mRNA-based COVID-19 vaccination was collected from each study. Analysis was performed by calculating the pooled prevalence rate, and the association was determined using the Z-test. Data networking was performed using the Bayesian method. Results: A total of 18 papers was included in our analysis. We found that the cumulative prevalence of myocarditis was 1.7, 1.9, 1.2, and 1.1 per 100,000 population after vaccination with different types of mRNA-based COVID-19 vaccines, namely all mRNA COVID-19 vaccines, BNT162b1, mRNA-1273, and the combination of BNT162b1 and mRNA-1273, respectively. Moreover, the results revealed that BNT162b1 vaccination increased the risk of myocarditis by 1.64- and 1.71-folds compared to mRNA-1273 and the combination of BNT162b2 and mRNA-1273, respectively. Similar risks of developing myocarditis were observed after mRNA-1273 and the combination of BNT162b1 and mRNA-1273 vaccination. Conclusions: Our findings suggest the cumulative prevalence of myocarditis after mRNA-based COVID-19 vaccination with maximum prevalence was observed after BNT162b2 administration. BNT162b2 was associated with a higher risk of developing myocarditis than the other mRNA-based COVID-19 vaccines.
- Open Access
- 10 March 2022
- Published by F1000 Research Ltd in F1000Research
- Vol. 11, 299
Seroconversion rates among different designs of COVID-19 vaccines: a network meta-analysis of randomized controlled trials
BACKGROUND: The COVID-19 vaccination program, which uses various types of vaccines, has been applied since the beginning of 2021. However, the efficacy in the context of seroconversion rate remains unclear. OBJECTIVE: To assess the seroconversion rates among different COVID-19 vaccines using a network meta-analysis approach. METHODS: A network meta-analysis of randomized controlled trials (RCTs) was conducted during the study period. Data of interest, such as seroconversion rate and the type of COVID-19 vaccine, were extracted from each study. The analysis was performed using single-arm analysis by calculating the cumulative seroconversion rate. A network meta-analysis was conducted using the Bayesian method. RESULTS: A total of 31 RCTs were included in our analysis. Our pooled calculation revealed that the seroconversion rates of inactivated messenger ribonucleic acid (mRNA), protein subunit, and vector COVID-19 vaccines during the follow-up periods were 93.2%, 93.9%, 65.3%, and 54.7%, respectively, at ≤ 15 days; 96.0%, 94.8%, 91.2%, and 89.7%, respectively, between days 16–30; and 98.5%, 98.6%, 98.5%, and 96.2%, respectively, between days 31–60.The indirect comparison revealed that in the follow-up periods of ≤ 15 and 16–30 days, the inactivated and mRNA COVID-19 vaccines had superior seroconversion rates compared with those of the protein subunit and vector vaccines. In the follow-up period of 31–60 days, the highest seroconversion rates were found in the inactivated, mRNA, and protein subunit COVID-19 vaccines. CONCLUSION: This study provides valuable information regarding the comparison of seroconversion rates of COVID-19 vaccines.
- 10 March 2022
- Published by F1000 Research Ltd in F1000Research
- Vol. 11, 299
Open AccessSeroconversion rates among different designs of COVID-19 vaccines: a network meta-analysis of randomized controlled trials
BACKGROUND: The COVID-19 vaccination program, which uses various types of vaccines, has been applied since the beginning of 2021. However, the efficacy in the context of seroconversion rate remains unclear. OBJECTIVE: To assess the seroconversion rates among different COVID-19 vaccines using a network meta-analysis approach. METHODS: A network meta-analysis of randomized controlled trials (RCTs) was conducted during the study period. Data of interest, such as seroconversion rate and the type of COVID-19 vaccine, were extracted from each study. The analysis was performed using single-arm analysis by calculating the cumulative seroconversion rate. A network meta-analysis was conducted using the Bayesian method. RESULTS: A total of 31 RCTs were included in our analysis. Our pooled calculation revealed that the seroconversion rates of inactivated messenger ribonucleic acid (mRNA), protein subunit, and vector COVID-19 vaccines during the follow-up periods were 93.2%, 93.9%, 65.3%, and 54.7%, respectively, at ≤ 15 days; 96.0%, 94.8%, 91.2%, and 89.7%, respectively, between days 16–30; and 98.5%, 98.6%, 98.5%, and 96.2%, respectively, between days 31–60.The indirect comparison revealed that in the follow-up periods of ≤ 15 and 16–30 days, the inactivated and mRNA COVID-19 vaccines had superior seroconversion rates compared with those of the protein subunit and vector vaccines. In the follow-up period of 31–60 days, the highest seroconversion rates were found in the inactivated, mRNA, and protein subunit COVID-19 vaccines. CONCLUSION: This study provides valuable information regarding the comparison of seroconversion rates of COVID-19 vaccines.